Madrid (ots/PRNewswire) - The United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to Yondelis in the indication of Soft Tissue Sarcoma (STS). The sponsor of this application in the US is our partner Johnson & Johnson Pharmaceutical Research & Development. The European Commission (E.C.) already granted Orphan Drug status for this ...
Lausanne (ots) - IMD, one of the world's top business schools, announces that its Zurich Alumni Club and Accenture Zürich, a leading worldwide strategy consultancy, have successfully completed a pro bono consulting project with UNICEF Switzerland (Baumackerstrasse 24, 8050 Zürich), world-renowned supporter of children's causes in the United Nations member ...
Indianapolis (ots/PRNewswire) - - New Analysis Showed Teriparatide Prevented Fracture Risk Associated with Increasing Number, Severity of Osteoporotic Fractures Data presented at the American Society for Bone and Mineral Research (ASBMR) 26th annual meeting in Seattle, Wash., showed that the number and severity of prior fractures are strong predictors of future fractures in postmenopausal women with ...
Indianapolis (ots/PRNewswire) - Data presented at the 26th annual meeting of the American Society for Bone and Mineral Research (ASBMR), Seattle, Wash., shows that the ability of teriparatide to prevent fractures remained consistent regardless of pretreatment bone turnover status.(1) Bone is living tissue that constantly regenerates itself by breaking down and ...
Madrid, Spain (ots/PRNewswire) - PharmaMar announced today that Aplidin(R), its second marine-derived compound in Phase II clinical development, has been granted orphan drug status by the United States (US) Food and Drug Administration (FDA), for the treatment of Multiple Myeloma (MM). This is the second orphan drug designation granted to Aplidin by the FDA. The ...
Dayton, Ohio (ots/PRNewswire) - Robbins & Myers, Inc. (NYSE: RBN) announced today that its Board of Directors approved a regular quarterly cash dividend payment of US $.055 per share that is payable on October 29, 2004 to shareholders of record as of October 15, 2004. The Company also announced that its annual shareholders' meeting will be held December 8, 2004 in Dayton, Ohio, with record date set of October 15, ...
Geneva, Switzerland (ots/PRNewswire) - PharmaMar presented data from six studies, four of which were from pharmacogenomics research projects at the EORTC-NCI-AACR[1] International Conference on Molecular Targets and Cancer Therapeutics, held in Geneva, Switzerland, from 28 September to 1 October 2004. ...
Montreal (ots/PRNewswire) - ProMetic Life Sciences (PLI:TSX) announced today the administrative reorganisation of its communications and business development structure. By implementing these changes, the Company is focusing its business development activities in key markets providing optimal growth opportunities namely in the United States, Europe, Asia and the Middle East. ProMetic can better achieve this goal ...
Basel, Switzerland (ots/PRNewswire) - - Study Shows a Significant Improvement in Overall Survival for Patients Given Tarceva Combined with Chemotherapy Versus Chemotherapy Alone Roche, Genentech, Inc. and OSI Pharmaceuticals, Inc., today announced positive results from a phase III study of investigational drug Tarceva (erlotinib) in locally advanced or ...
Boehringer Ingelheim GmbH and Eli Lilly and Company
Indianapolis, Indiana and Ingelheim, Germany (ots/PRNewswire) - Eli Lilly and Company and Boehringer Ingelheim today announced that the Committee for Medicinal Products in Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending approval of duloxetine for the treatment ...
Vienna, Austria (ots/PRNewswire) - - Prograf(R)-sirolimus Combination is Effective in Kidney Transplantation - Clinical Benefits With Prograf(R) for Heart Transplant Patients Six-month data from a new European study, presented today by Dr Stefan Vitko (IKEM, Prague, Czech Republic) at the XX International Congress of the Transplantation Society, ...
Edmonton, Alberta, Canada (ots/PRNewswire) - Isotechnika Inc. announced today they have received the interim results of the QTc trial for its lead immunosuppressive drug, ISA247 from eResearch Technology Inc. The study, conducted by Pracs in Fargo, North Dakota was designed as a double blind, parallel group, placebo and moxifloxacin controlled, randomized, single dose QTc study of trans-ISA247 in healthy volunteers. In ...
Dr Patrick Marcellin, Beaujon Hospital
Paris (ots/PRNewswire) - - World Experts Meet in Paris for the First International Conference on the Management of Patients With Viral Hepatitis The world's leading hepatitis experts, along with more than 850 physicians, will be meeting in Paris on September 10 and 11 for the first International Conference on the Management of Patients with Viral Hepatitis. The conference will review the most ...
Houston (ots/PRNewswire) - - Study Shows Liver Toxicities Experienced by Patients on Bosentan Were Not Experienced on Thelin Encysive Pharmaceuticals (Nasdaq: ENCY) today announced the presentation of new clinical data on Thelin(TM) (sitaxsentan) in pulmonary arterial hypertension (PAH), at the European ...
Munich, Germany (ots/PRNewswire) - - Researchers conclude LAF237 positively influences both insulin production and utilisation in type 2 diabetes The investigational drug LAF237, the first in a new class of oral anti- diabetes agents, significantly improved glycemic control in patients with type 2 ...
Vienna, Austria (ots/PRNewswire) - Transplant specialists from around the world met yesterday to discuss controversial, radical and novel approaches to minimise the impact of the current organ shortage problem in a bid to help desperate patients in need of a kidney transplant. The full-day symposium, which ...
London and Brussels (ots/PRNewswire) - - RISC Study, Largest of its Kind, Reaches Recruitment Milestone The European Group for the study of Insulin Resistance (EGIR) announced today that the clinical trial recruitment milestone of 1,200 subjects has been reached in the Relationship between Insulin Sensitivity and Cardiovascular disease risk (RISC) study - ...
Montreal (ots/PRNewswire) - - Potential use Includes Anaemia Induced by Chemotherapy and Renal Diseases - Market of Above US$10 Billion ProMetic Life Sciences Inc. (TSX: PLI) is pleased to announce that its scientists have confirmed evidence of PBI-1402's positive effect on the formation of red blood cells in bone marrow. This proliferation is additive ...
Copenhagen, Denmark (ots/PRNewswire) - Genmab A/S (CSE: GEN) announced today that cutaneous T-cell lymphoma (CTCL) patients in the HuMax-CD4 Phase II studies achieved long lasting responses, with an average response duration of more than 6.6 months. This duration of response data is based on an analysis of responding mycosis fungoides (MF) patients at all dose ...
Houston (ots/PRNewswire) - - Abstract Presented on Extension Data From STRIDE-1 Trial in Pulmonary Arterial Hypertension Encysive Pharmaceuticals (Nasdaq: ENCY) today announced the presentation of data from a clinical study of Thelin(TM) (sitaxsentan) in pulmonary arterial hypertension (PAH), at the European Society of Cardiology Annual Congress in Munich. ...
Munich, Germany (ots/PRNewswire) - - Data from this and other Diovan(R)(valsartan) studies, including VALIANT and Val-HeFT presented at the European Society Congress 2004 An analysis of more than 39,000 potential participants in the global NAVIGATOR (Nateglinide And Valsartan in Impaired Glucose Tolerance ...
Basel, Switzerland (ots/PRNewswire) - - Roche files marketing application for Tarceva with European health authorities Roche today submitted a Marketing Authorisation Application to the European health authorities for its new cancer drug Tarceva (erlotinib) for the treatment of advanced non-small cell lung cancer (NSCLC). NSCLC is the most common form of lung cancer, which in itself is the most frequent cancer ...
Basel, Switzerland (ots/PRNewswire) - - 4.5 Million Americans Suffer from Constipation Most of the Time Novartis Pharma AG announced that the U.S. Food and Drug Administration (FDA) today approved a supplemental indication for its pro-motility agent Zelnorm(R) (tegaserod maleate) for the treatment of chronic idiopathic constipation in male and female ...
Tampere, Finland (ots/PRNewswire) - Inion, one of the leading companies in the field of developing biodegradable medical implants, announces FDA 510(k) clearance of its Trinion(TM) Meniscus Screw for use in knee cartilage repair. This clearance allows Inion's Trinion(TM) screws to be marketed and sold in the US, complementing the previously offered HexalonTM biodegradable cruciate ligament repair screw, in the world's ...
Research Triangle Park, North Carolina (ots/PRNewswire) - - Strong net new business growth, up 31% for first half of 2004 - Fourth consecutive half-year increase in total net new business wins Quintiles Transnational Corp. today announced financial results for the quarter ended June 30, 2004. Net revenue for second quarter 2004 was US$425.8 million versus US$408.4 million for the same period in 2003. Net ...
Lausanne, Switzerland and Irvine, California (ots/PRNewswire) - Please add the following ticker symbols to the first paragraph of the release. (SWX/Euronext: ISO; TSX: ISO; Reuters: ISON.S; Reuters: ISO.TO; ASX: ISON.AS) IsoTis OrthoBiologics (SWX/Euronext: ISO; TSX: ISO; Reuters: ISON.S; Reuters: ISO.TO; ASX: ISON.AS) today reported a 16% increase in orthobiologics sales of US$12.9 million for the first six ...
/ON HOLD ON HOLD ON HOLD -- IsoTis OrthoBiologics, EDB1011437 Please place the following release: "IsoTis Announces 16% H1 Orthobiologics Sales Growth, and Provides Further 04 & 05 Guidance" ON HOLD. ots Originaltext: IsoTis OrthoBiologics Im Internet recherchierbar: http://www.newsaktuell.ch Contact: Hans Herklots, +41-21-620-6011, Fax: +41-21-620-6060, hans.herklots@isotis.com, or Louis G. Plourde, ...
Lausanne, Switzerland and Irvine, California (ots/PRNewswire) - IsoTis OrthoBiologics (SWX/Euronext: ISON; TSX: ISO) today reported a 16% increase in orthobiologics sales of US$12.9 million for the first six months of fiscal 2004, compared to pro-forma orthobiologics sales of US$11.1 million for the first six months of 2003. Sales for the second quarter 2004 were ...
Cambridge, England, Montreal, Canada. Washington D.c. and Lille, France (ots/PRNewswire) - - Initial European Roll out Planned for 2005 - Strategic Alliance to Include Development of Filters for Viruses - MacoPharma to Market and Distribute the Products - Financial Arrangement Based on Revenue ...
Basel, Switzerland (ots/PRNewswire) - Novartis Pharma AG announced today that the Committee for Medicinal Products for Human Use (CHMP), adopted a positive opinion recommending that the European Commission (EC) grant a Marketing Authorisation for Emselex(R) (darifenacin hydrobromide), 7.5mg and 15mg, for the treatment of overactive bladder (OAB) in all 25 European ...